# **BDNF VAL66MET POLYMORPHISM IS NOT ASSOCIATED WITH CORONARY ATHEROSCLEROSIS IN CZECH PATIENTS**

M. Petrek<sup>1</sup>, N. Motakova<sup>1</sup>, A. Stahelova<sup>1</sup>, F. Mrazek<sup>1</sup>, J. Petrkova<sup>2</sup>

<sup>1</sup>Immunology, Palacky University, <sup>2</sup>Internal Medicine I, Faculty Hospital, Olomouc, Czech Republic.



Introduction

ULTNÍ NEMOCNICE

Brain-derived neurotrophic factor (BDNF) has been implicated in the pathogenesis of coronary artery disease (CAD).

Recently, human BDNF Val66Met polymorphism has been associated with CAD in Chinese population [1] and this growth factor has been implicated as a plausible player in regulation of neuro-hormonal processes in patients with cardiovascular disease [2].

[1] Jiang H et al. BDNF Val66Met polymorphism is associated with unstable angina. Clin Chim Acta 2009; 400:3-7

[2] Erasmus RT. The brain and heart: Dancing in unison? Clin Chim Acta 2009; 400:1-2

Study subjects: A total of 397 unrelated individuals were enrolled into the study: 217 Czech patients from Olomouc area [age, median (range): 53 (25-79); males/females: 185/32] and 180 Czech healthy individuals [age, median (range): 29 (18-64); males/females: 95/85] serving as control population.

**Patients and Methods** 

Diagnostic criteria for myocardial infarction (MI) were compatible with those recommended by an international consensus. Informed consent was obtained from all patients and controls.

Genotyping for BDNF Val66Met rs6265 G / A polymorphism was performed using qRT-PCR with "TaqMan" probes (Applied Biosystems, Assay ID C\_11592758\_10, Fig. 1).

The genotyping results were verified using the independent technique (PCR-SSP) with the primers as follows:

5' GGCTGACACTTTCGAACACG with 5' GTTACCCACTCACTAATACTG for 66Val allele and 5' GGCTGACACTTTCGAACACA with 5' GTTACCCACTCACTAATACTG for 66Met allele.

Statistical analysis: Consistency of the distribution of BDNF Val66Met genotypes with Hardy-Weinberg expectation was verified by the "x2 goodness-of-fit" test, comparisons of the frequencies of BDNF Val66Met variants in the studied groups was performed by  $\chi^2$  test.

#### **Rationale and Aim**

To further explore a possible role of this **BDNF** polymorphism as a genetic modifier in CAD we have investigated its association with myocardial infarction in the Czech population.

**Figure 1**: Genotyping of SNP BDNF rs6265 by qRT-PCR – interpretation



Genotype and allele frequencies of the BDNF Val66Met polymorphism did not differ between the patients and control subjects (p> 0.05, **Tab. 1**). Two investigated groups also did not differ in carriage rates (phenotype frequencies) of the BDNF Val66Met polymorphism.

Similarly, no association with MI was found when male/female MI patients were compared with control subjects separately (Tab. 2)

#### **Results**

The distribution of *BDNF* Val66Met genotypes complied to Hardy-Weinberg equilibrium in MI patients and control subjects (p > 0.05)

## **Table 1:** Distribution of BDNF Val66Met polymorphism in MI patients and controls

<i>BDNF</i> rs6265 G/A (Val66Met)		Czech population		
		MI	Controls	
		(N=217)	(N=180)	
Genotypes	GG	149(0.687)	127(0.706)	
	GA	59(0.272)	44(0.244)	
	AA*	9(0.041)	9(0.050)	
Alleles	G	357(0.823)	298(0.828)	
	A†	77(0.177)	62(0.172)	
Carriers A <sup>‡</sup>		68(0.313)	53(0.294)	

# Table 2: Distribution of BDNF Val66Met

polymorphism in MI patients and controls by gender

<i>BDNF</i> rs6265 G/A (Val66Met)		Czech population			
		MI		Controls	
		(N=217)		(N=180)	
		Male	Female	Male	Female
Genotypes	GG	125(0.676)	24(0.75)	69(0.726)	58(0.682)
	GA	54(0.292)	5(0.156)	21(0.221)	23(0.271)
	AA*	6(0.032)	3(0.094)	5(0.053)	4(0.047)
Alleles	G	304(0.822)	53(0.828)	159(0.837)	139(0.181)
	A†	66(0.178)	11(0.172)	31(0.163)	31(0.182)
Carriers	A‡	60(0.324)	8(0.25)	26(0.274)	27(0.318)

## Conclusion

The BDNF Val66Met polymorphism is not associated with myocardial infarction

#### in Czech population.

We could not, therefore, replicate the observation from China [1], which suggested that BDNF Met/Met genotype is a genetic modifier in CAD.

Investigations in further centres and/or populations [2] are, therefore, necessary to obtain more information on possible role of BDNF genetic variability in coronary artery disease.

[1] Jiang H et al. *Clin Chim Acta* 2009; 400:3-7; [2] Little J et al. Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement. Hum Genet 2009, 125:131-51.

Grant support: MSM ME-856 and MSM6198959205, PU project SV LF\_2010\_008.